185 related articles for article (PubMed ID: 37698559)
1. Ulcerative Colitis in Adults: A Review.
Gros B; Kaplan GG
JAMA; 2023 Sep; 330(10):951-965. PubMed ID: 37698559
[TBL] [Abstract][Full Text] [Related]
2. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
[TBL] [Abstract][Full Text] [Related]
3. The impact of biological interventions for ulcerative colitis on health-related quality of life.
LeBlanc K; Mosli MH; Parker CE; MacDonald JK
Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD008655. PubMed ID: 26393522
[TBL] [Abstract][Full Text] [Related]
4. A comprehensive review and update on ulcerative colitis
Gajendran M; Loganathan P; Jimenez G; Catinella AP; Ng N; Umapathy C; Ziade N; Hashash JG
Dis Mon; 2019 Dec; 65(12):100851. PubMed ID: 30837080
[TBL] [Abstract][Full Text] [Related]
5. P056 Real life experience with the use of tofacitinib in ulcerative colitis in Colombia: case series.
Parra Izquierdo V; Frias-Ordoñez J; Galindo P; Romero-Sanchez C; Florez C
Am J Gastroenterol; 2021 Dec; 116(Suppl 1):S14-S15. PubMed ID: 37461974
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of tofacitinib compared with infliximab, adalimumab, golimumab, vedolizumab and ustekinumab for the treatment of moderate to severe ulcerative colitis in Germany.
Sardesai A; Dignass A; Quon P; Milev S; Cappelleri JC; Kisser A; Modesto I; Sharma PP
J Med Econ; 2021; 24(1):279-290. PubMed ID: 33502905
[TBL] [Abstract][Full Text] [Related]
7. Maintenance therapy options for ulcerative colitis.
Chaparro M; Gisbert JP
Expert Opin Pharmacother; 2016 Jul; 17(10):1339-49. PubMed ID: 27240112
[TBL] [Abstract][Full Text] [Related]
8. Oral Janus kinase inhibitors for maintenance of remission in ulcerative colitis.
Davies SC; Hussein IM; Nguyen TM; Parker CE; Khanna R; Jairath V
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD012381. PubMed ID: 31984480
[TBL] [Abstract][Full Text] [Related]
9. Effect of Long-Term Mesalamine Therapy on Cancer-Associated Gene Expression in Colonic Mucosa of Patients with Ulcerative Colitis.
Bajpai M; Seril DN; Van Gurp J; Geng X; Alvarez J; Minacapelli CD; Gorin S; Das KK; Poplin E; Cheng J; Amenta PS; Das KM
Dig Dis Sci; 2019 Mar; 64(3):740-750. PubMed ID: 30478770
[TBL] [Abstract][Full Text] [Related]
10. Early predictors of colectomy and long-term maintenance of remission in ulcerative colitis patients treated using anti-tumour necrosis factor therapy.
Subramaniam K; Richardson A; Dodd J; Platten J; Shadbolt B; Pavli P
Intern Med J; 2014 May; 44(5):464-70. PubMed ID: 24612209
[TBL] [Abstract][Full Text] [Related]
11. [Management of diagnosis and treatment in ulcerative colitis].
Klotz C; Barret M; Dhooge M; Oudjit A; Chaussade S; Coriat R; Abitbol V
Presse Med; 2015 Feb; 44(2):144-9. PubMed ID: 25534469
[TBL] [Abstract][Full Text] [Related]
12. [Risk factors for ulcerative colitis associated colorectal cancers in a Hungarian cohort of ulcerative colitis patients].
Lakatos L; Mester G; Erdélyi Z; David G; Pandúr T; Balogh M; Fischer S; Vargha P; Lakatos PL
Orv Hetil; 2006 Jan; 147(4):175-81. PubMed ID: 16515026
[TBL] [Abstract][Full Text] [Related]
13. Comparative Speed of Early Symptomatic Remission With Advanced Therapies for Moderate-to-Severe Ulcerative Colitis: A Systematic Review and Network Meta-Analysis.
Ahuja D; Murad MH; Ma C; Jairath V; Singh S
Am J Gastroenterol; 2023 Sep; 118(9):1618-1625. PubMed ID: 36976548
[TBL] [Abstract][Full Text] [Related]
14. Characteristics of patients with moderate-to-severe ulcerative colitis treated with vedolizumab: results from a Polish multicenter, prospective, observational real-life study (the POLONEZ study).
Cichoż-Lach H; Michalak A; Kopertowska-Majchrzak M; Eder P; Stawczyk-Eder K; Waszak K; Talar-Wojnarowska R; Zatorski H; Solarska-Półchłopek A; Chmielnicki J; Filip R; Pękala A; Janiak M; Skrobot K; Kasińska E; Krogulecki M; Królikowski P; Kłopocka M; Liebert A; Poniewierka E; Smoła I; Gąsiorowska A; Kaczka A; Wypych J; Wojciechowski K; Drygała S; Zagórowicz E
Therap Adv Gastroenterol; 2021; 14():17562848211036456. PubMed ID: 34484422
[TBL] [Abstract][Full Text] [Related]
15. Ulcerative colitis: epidemiology, diagnosis, and management.
Feuerstein JD; Cheifetz AS
Mayo Clin Proc; 2014 Nov; 89(11):1553-63. PubMed ID: 25199861
[TBL] [Abstract][Full Text] [Related]
16. Mild-to-moderate ulcerative colitis: your role in patient compliance and health care costs.
Tindall WN; Boltri JM; Wilhelm SM
J Manag Care Pharm; 2007 Sep; 13(7 Suppl A):S2-12; quiz S13-4. PubMed ID: 17874873
[TBL] [Abstract][Full Text] [Related]
17. The incidence of remission and indicators of inadequate response to advanced therapy in patients with ulcerative colitis: results from medical charts in the United Kingdom.
Lindsay JO; Picker N; Kromer D; Smyth M; Patel H
Curr Med Res Opin; 2023 May; 39(5):681-689. PubMed ID: 36951899
[TBL] [Abstract][Full Text] [Related]
18. [Management of ulcerative colitis].
Rammert Ch; Kullak-Ublick GA
Ther Umsch; 2003 Mar; 60(3):145-50. PubMed ID: 12693317
[TBL] [Abstract][Full Text] [Related]
19. Ulcerative Colitis.
Feuerstein JD; Moss AC; Farraye FA
Mayo Clin Proc; 2019 Jul; 94(7):1357-1373. PubMed ID: 31272578
[TBL] [Abstract][Full Text] [Related]
20. Pediatric ulcerative colitis: a practical guide to management.
Regan BP; Bousvaros A
Paediatr Drugs; 2014 Jun; 16(3):189-98. PubMed ID: 24723200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
